Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.

Immune-related pneumonitis is a clinically relevant and potentially life-threatening adverse event. We performed a systematic review and network meta-analysis to compare the risk of immune-related pneumonitis among different PD1/PD-L1 inhibitor-related therapeutic regimens.